SYN Key Statistics, Chart & Performance
The current stock price of SYN is 1.02 USD. In the past month the price decreased by -25.55%. In the past year, price decreased by -76.54%.
SYN Latest News, Press Relases and Analysis
SYN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.85 | 398.26B | ||
| AMGN | AMGEN INC | 15.46 | 182.05B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.56 | 108.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 77.22B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 908.94 | 61.24B | ||
| INSM | INSMED INC | N/A | 45.03B | ||
| NTRA | NATERA INC | N/A | 32.53B | ||
| BIIB | BIOGEN INC | 10.47 | 25.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.22 | 20.71B | ||
| INCY | INCYTE CORP | 15.99 | 20.15B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About SYN
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 16 full-time employees. The firm is focused on the development of oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient’s immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.
Company Info
SYNTHETIC BIOLOGICS INC
Suite 412, 155 Gibbs Street
Rockville MARYLAND 20850 US
CEO: Steven A. Shallcross
Employees: 16
Phone: 17343327800.0
SYNTHETIC BIOLOGICS INC / SYN FAQ
What does SYN do?
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 16 full-time employees. The firm is focused on the development of oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient’s immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.
What is the current price of SYN stock?
The current stock price of SYN is 1.02 USD. The price increased by 0.99% in the last trading session.
What is the dividend status of SYNTHETIC BIOLOGICS INC?
SYN does not pay a dividend.
How is the ChartMill rating for SYNTHETIC BIOLOGICS INC?
SYN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does SYNTHETIC BIOLOGICS INC belong to?
SYNTHETIC BIOLOGICS INC (SYN) operates in the Health Care sector and the Biotechnology industry.
SYN Technical Analysis
SYN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SYN. SYN has a bad profitability rating. Also its financial health evaluation is rather negative.
SYN Financial Highlights
Over the last trailing twelve months SYN reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 71.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.59% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SYN Forecast & Estimates
6 analysts have analysed SYN and the average price target is 6.12 USD. This implies a price increase of 500% is expected in the next year compared to the current price of 1.02.